A Pilot Study of Combination Chemotherapy for Poor PS Patients with Small Cell Lung Cancer.
スポンサーリンク
概要
- 論文の詳細を見る
Sixteen cases of small cell lung cancer (SCLC) with poor prognosis were entered in a pilot study consisting of CDDP 30mg/m<SUP>2</SUP>, VCR 1mg/body×2 days, ADM 20mg/m<SUP>2</SUP>, ACNU 30mg/m<SUP>2</SUP> and MMC 3mg/m<SUP>2</SUP>. All patients had extensive disease, and their performance status (PS) was 3 or 4. Among 15 eligible patients, 1 complete and 11 partial responses were obtained, resulting in an overall response rate of 75%. Although the median survival time was 3.7 months, the PS improved in 10 patients. Toxicity levels were acceptable, and no treatment-related death occurred. These results suggested that SCLC case with poor PS could improve their quality of life, using this combination chemotherapy.
- 特定非営利活動法人 日本肺癌学会の論文
特定非営利活動法人 日本肺癌学会 | 論文
- 診療科からみた新しいTNM病期分類（UICC-7）の問題点と課題?画像診断からみた問題点と課題?
- 新潟県における肺がんの解析
- 慢性血栓塞栓性肺高血圧症合併肺腺癌に対する左上葉切除術を施行した1例
- 肺がん検診における判定基準の改訂（2）：B，C，D判定に関して
- 片側性多発脳神経障害（Garcin症候群）を契機に発見され，化学療法により神経症状の改善を得た小細胞肺癌の1例